Grufity logoGrufity logo

Thermo Fisher Scientific Inc Stock Research

TMO

557.09USD+14.39(+2.65%)Delayed

Market Summary

USD557.09+14.39
Delayed
2.65%

TMO Alerts

TMO Stock Price

TMO RSI Chart

TMO Valuation

Market Cap

218.4B

Price/Earnings (Trailing)

31.38

Price/Sales (Trailing)

4.86

EV/EBITDA

25.01

Price/Free Cashflow

31.6

TMO Price/Sales (Trailing)

TMO Profitability

EBT Margin

17.44%

Return on Equity

15.83%

Return on Assets

7.16%

Free Cashflow Yield

3.16%

TMO Fundamentals

TMO Revenue

Revenue (TTM)

44.9B

Revenue Y/Y

6.99%

Revenue Q/Q

7.24%

TMO Earnings

Earnings (TTM)

7.0B

Earnings Y/Y

-5.12%

Earnings Q/Q

5.07%

Price Action

52 Week Range

475.77618.36
(Low)(High)

Last 7 days

-2.2%

Last 30 days

-5.6%

Last 90 days

-2%

Trailing 12 Months

-1.4%

TMO Financial Health

Current Ratio

1.48

Debt/Equity

0.66

Debt/Cashflow

0.32

TMO Investor Care

Dividend Yield

0.22%

Dividend/Share (TTM)

1.2

Buy Backs (1Y)

0.51%

Diluted EPS (TTM)

17.63

Peers (Alternatives to Thermo Fisher Scientific)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
218.4B
44.9B
-5.62% -1.44%
31.38
4.86
14.55% -9.94%
35.5B
4.6B
5.65% -27.02%
-8.07
7.75
1.28% -677.95%
32.5B
3.9B
-7.42% 9.05%
37.3
8.3
5.43% 13.46%
18.2B
3.0B
-10.97% -4.88%
25.66
6.11
6.68% 2.15%
10.8B
2.5B
-3.73% 16.11%
36.41
4.27
4.67% 7.04%
MID-CAP
2.4B
509.7M
46.19% 25.15%
-16.73
4.74
5.24% -1628.17%
SMALL-CAP
2.0B
128.3M
-11.70% -1.09%
-6.37
15.61
-1.69% -73.40%
1.2B
185.3M
-5.41% -23.53%
-6
6.49
20.06% 3.42%
450.3M
105.5M
-12.44% -50.56%
-4.66
4.27
-4.55% -67.63%
341.8M
27.8M
-23.57% -31.43%
-2.58
12.29
54.62% -83.06%
271.1M
138.6M
-29.13% -76.08%
-8.07
1.96
32.30% -57.86%
121.5M
72.0M
-9.68% -16.83%
-7.37
1.69
6.82% 39.11%
117.4M
113.3M
-15.92% -55.18%
-12.34
1.04
-4.68% -3204.17%
80.8M
42.4M
-41.42% -80.17%
-1.03
1.9
30.40% -43.67%

Financials for Thermo Fisher Scientific

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue1.7%44,91544,16742,82041,12339,211
  S&GA Expenses0.2%8,9938,9728,7688,4588,007
  R&D Expenses-0.1%1,4711,4721,4721,4501,406
Costs and Expenses4.1%36,52235,09733,18231,32329,183
EBITDA0.7%9,5479,4859,97910,058-
EBITDA Margin-1.0%0.21*0.21*0.23*0.24*-
Earnings Before Taxes-1.1%7,8357,9208,4968,6288,841
EBT Margin-2.7%0.17*0.18*0.20*0.21*-
Interest Expenses17.5%726618573547536
Net Income-1.2%6,9607,0457,4507,6117,728
Net Income Margin-2.9%0.15*0.16*0.17*0.19*-
Free Cahsflow23.4%6,9115,6006,3367,001-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets7.3%97,15490,53690,57992,74795,123
  Current Assets30.7%25,22919,29918,10018,77620,113
    Cash Equivalents192.0%8,5242,9191,8882,7524,477
  Inventory-1.5%5,6345,7225,6685,4835,051
  Net PPE7.6%9,2808,6288,5298,4488,333
  Goodwill1.7%41,19640,48841,06641,72141,924
  Current Liabilities53.0%17,01011,11810,99712,07013,436
  Long Term Debt2.7%28,90928,15029,25031,38932,333
Shareholder's Equity1.0%43,97843,54942,35441,01840,793
  Retained Earnings3.6%41,91040,45239,07437,52835,431
  Additional Paid-In Capital0.9%16,74316,59616,46716,29216,174
Shares Outstanding0%392392392--
Minority Interest-8.5%54.0059.0061.0062.0062.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations12.7%9,1548,1248,8379,5369,312
  Share Based Compensation-0.6%307309283257230
Cashflow From Investing89.4%-2,159-20,326-20,397-20,604-21,932
Cashflow From Financing-186.0%-2,8103,2666,4578,2866,581
  Dividend Payments3.2%455441425411395
  Buy Backs50.0%3,0002,0002,0002,0002,000

Risks for TMO

What is the probability of a big loss on TMO?

16.1%


Probability that Thermo Fisher Scientific stock will be more than 20% underwater in next one year

0%


Probability that Thermo Fisher Scientific stock will be more than 30% underwater in next one year.

0%


Probability that Thermo Fisher Scientific stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TMO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Thermo Fisher Scientific was unfortunately bought at previous high price.

Drawdowns

Returns for TMO

Cumulative Returns on TMO

21.9%


10-Year Cumulative Returns

21.8%


7-Year Cumulative Returns

21.1%


5-Year Cumulative Returns

22.0%


3-Year Cumulative Returns

What are the long-term rolling returns for TMO?

FIve years rolling returns for Thermo Fisher Scientific.

Annualized Returns

Which funds bought or sold TMO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-3.72
947,853
21,596,900
0.60%
2023-03-10
BAILLIE GIFFORD & CO
reduced
-4.55
24,690,800
703,173,000
0.73%
2023-03-10
MATHER GROUP, LLC.
added
25.16
348,517
1,320,520
0.03%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-6.4
2,797,580
174,467,000
0.19%
2023-03-08
Capital Asset Advisory Services LLC
reduced
-4.91
103,386
2,105,390
0.17%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
unchanged
-
144,395
1,827,400
0.29%
2023-03-07
Great Lakes Retirement, Inc.
new
-
626,709
626,709
0.16%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-2.72
5,345,000
100,453,000
0.50%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
reduced
-0.11
2,201,530
28,235,500
1.75%
2023-03-03
Crumly & Associates Inc.
reduced
-1.34
46,034
691,034
0.26%

1–10 of 47

Latest Funds Activity

Are funds buying TMO calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own TMO
No. of Funds

Thermo Fisher Scientific News

MarketBeat

Hennion & Walsh Asset Management Inc. Trims Stake in Thermo ....

MarketBeat,
4 hours ago

DirectorsTalk Interviews

Seeking Alpha

Schedule 13G FIlings of Thermo Fisher Scientific

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.30%
32,534,676
SC 13G/A
Feb 03, 2023
blackrock inc.
7.9%
30,790,122
SC 13G/A
Feb 10, 2022
vanguard group inc
7.89%
31,103,788
SC 13G/A
Feb 01, 2022
blackrock inc.
7.9%
30,982,611
SC 13G
Feb 10, 2021
vanguard group inc
7.82%
30,997,381
SC 13G/A
Feb 01, 2021
blackrock inc.
7.4%
29,504,221
SC 13G/A
Feb 12, 2020
vanguard group inc
7.77%
31,187,697
SC 13G/A
Feb 06, 2020
blackrock inc.
7.0%
28,202,856
SC 13G/A

TMO Fair Value

Thermo Fisher Scientific fair value in different scenarios

The table shows the Fair Value estimates for Thermo Fisher Scientific for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

360.84

-35.23%

467.87

-16.02%

662.22

18.87%

962.67

72.80%

1245.53

123.58%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Thermo Fisher Scientific Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Thermo Fisher Scientific

View All Filings
Date Filed Form Type Document
Mar 15, 2023
4
Insider Trading
Mar 14, 2023
144
Notice of Insider Sale Intent
Mar 13, 2023
144
Notice of Insider Sale Intent
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading

Latest Insider Trading transactions for TMO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-14
CASPER MARC N
sold
-4,153,450
553
-7,500
chairman & ceo
2023-03-13
CASPER MARC N
sold
-4,083,690
544
-7,500
chairman & ceo
2023-03-05
Lagarde Michel
sold (taxes)
-73,286
559
-131
executive vice president & coo
2023-03-05
Pettiti Gianluca
sold (taxes)
-36,923
559
-66.00
executive vice president
2023-02-28
Williamson Stephen
sold (taxes)
-452,370
541
-835
sr. vp and cfo
2023-02-28
Pettiti Gianluca
sold (taxes)
-420,948
541
-777
executive vice president
2023-02-28
CASPER MARC N
sold (taxes)
-1,445,960
541
-2,669
chairman & ceo
2023-02-28
Boxer Michael A
sold (taxes)
-120,812
541
-223
svp and general counsel
2023-02-28
Holmes Joseph R.
sold (taxes)
-21,128
541
-39.00
vp & chief accounting officer
2023-02-28
Lagarde Michel
sold (taxes)
-552,053
541
-1,019
executive vice president & coo

1–10 of 50

Marc N. Casper
65535
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.

TMO Income Statement

2022-12-31
Consolidated Statement of Income - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues   
Revenues$ 44,915$ 39,211$ 32,218
Costs and operating expenses:   
Selling, general and administrative expenses8,9938,0076,930
Research and development expenses1,4711,4061,181
Restructuring and other costs11419799
Total costs and operating expenses36,52229,18324,424
Operating income8,39310,0287,794
Interest income2724365
Interest expense(726)(536)(553)
Other income/(expense)(104)(694)(76)
Income before income taxes7,8358,8417,230
Provision for income taxes(703)(1,109)(850)
Equity in earnings/(losses) of unconsolidated entities(172)(4)(3)
Net income6,9607,7286,377
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest1032
Net income attributable to Thermo Fisher Scientific Inc.$ 6,950$ 7,725$ 6,375
Earnings per share attributable to Thermo Fisher Scientific Inc.   
Basic (in dollars per share)$ 17.75$ 19.62$ 16.09
Diluted (in dollars per share)$ 17.63$ 19.46$ 15.96
Weighted average shares   
Basic (in shares)392394396
Diluted (in shares)394397399
Product revenues   
Revenues   
Revenues$ 28,548$ 30,361$ 25,306
Costs and operating expenses:   
Cost of revenues14,24713,59411,407
Service revenues   
Revenues   
Revenues16,3678,8506,912
Costs and operating expenses:   
Cost of revenues$ 11,697$ 5,979$ 4,807

TMO Balance Sheet

2022-12-31
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 8,524$ 4,477
Accounts receivable, less allowances of $189 and $1508,1157,977
Inventories5,6345,051
Contract assets, net1,312968
Other current assets1,6441,640
Total current assets25,22920,113
Property, plant and equipment, net9,2808,333
Acquisition-related intangible assets, net17,44220,113
Other assets4,0074,640
Goodwill41,19641,924
Total assets97,15495,123
Current liabilities:  
Short-term obligations and current maturities of long-term obligations5,5792,537
Accounts payable3,3812,867
Accrued payroll and employee benefits2,0952,427
Contract liabilities2,6012,655
Other accrued expenses3,3542,950
Total current liabilities17,01013,436
Deferred income taxes2,8493,837
Other long-term liabilities4,2384,540
Long-term obligations28,90932,333
Commitments and Contingencies
Redeemable noncontrolling interest116122
Thermo Fisher Scientific Inc. shareholders’ equity:  
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 440,668,112 and 439,154,741 shares issued441439
Capital in excess of par value16,74316,174
Retained earnings41,91035,431
Treasury stock at cost, 50,157,275 and 44,720,112 shares(12,017)(8,922)
Accumulated other comprehensive items(3,099)(2,329)
Total Thermo Fisher Scientific Inc. shareholders’ equity43,97840,793
Noncontrolling interests5462
Total equity44,03240,855
Total liabilities, redeemable noncontrolling interest and equity$ 97,154$ 95,123